A thorough electrocardiogram study of edoxaban, a novel factor xa inhibitor

Journal of Clinical Pharmacology

Volumn 51, Issue 8, 2011, Pages 1241-1246

  Mendell, J ^a   Basavapathruni, R ^a   Swearingen, D ^b   Draves, A ^b   Zhang, G ^a   Morganroth, J ^c  

^a DAIICHI SANKYO INC   (United States)

^b CELERION   (United States)

^c ERT   (United States)

Author keywords

DU 176b; Edoxaban; electrocardiogram; Factor Xa inhibitor; QTc interval

Indexed keywords

EDOXABAN; MOXIFLOXACIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HALF-LIFE; HUMANS; MALE; PYRIDINES; THIAZOLES; YOUNG ADULT;

EID: 79960734505     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010381901     Document Type: Article

References (10)

1. Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007 ; 98: 883-888 (Pubitemid 47555083)
2. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 ; 6: 1542-1549
3. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharm. 2010 ; 50: 743-753
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Clinical Evaluation of QT/QTC interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs E14. Geneva, Switzerland (2005). http://www.ich.org/LOB/media/MEDIA1476.pdf. Accessed December 19, 2009.
5. Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther. 2007 ; 81: 108-103
6. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010 ; 160: 635-642
7. Weitz JI, Connolly SJ, Patel I, et al. Randomized, parallel-group, multicenter, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010 ; 104: 633-641
8. Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008 ; 84: 475-480
9. World Medical Association. Declaration of Helsinki. 52nd WMA General Assembly. Edinburgh, Scotland, October2000.
10. Rohatagi S, Carrothers TJ, Kuwabara-Wagg J, Khariton TY. Is a thorough QTC study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs. J Clin Pharmacol. 2009 ; 49: 1284-1296